Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8852329 | 0.91 | TSHR (0.44) | CYP19A1CA2CA1FAAHPRSS1 | |
| SCHEMBL27712906 | 0.89 | PNMT (0.50) | CA2CA1CA5ACA9CA12 | |
| SCHEMBL14899836 | 0.89 | MGLL (0.41) | CYP19A1CA2 | |
| SCHEMBL30502958 | 0.87 | PNMT (0.52) | — | |
| SCHEMBL2343233 | 0.87 | PNMT (0.52) | — | |
| SCHEMBL1714793 | 0.85 | KMT2A (0.48) | — | |
| SCHEMBL1118911 | 0.85 | TAAR1 (0.47) | MMP2 | |
| SCHEMBL4135278 | 0.85 | LMNA (0.47) | CA2CA1FAAHPRSS1PRSS2 | |
| SCHEMBL2909170 | 0.85 | TAAR1 (0.47) | — | |
| SCHEMBL3294681 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070039874-A1 | Membranes and methods of treating membranes | GENERAL ELECTRIC COMPANY | 2007-02-22 | — | — | US | claimed |
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | COLLONGES FRANCOIS (FR) | 2003-10-30 | — | — | US | disclosed |
| US-6509499-B1 | Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-01-21 | — | — | US | disclosed |
| US-5656412-A | Energy-sensitive resist material and a process for device fabrication using an energy-sensitive resist material | LUCENT TECHNOLOGIES INC. (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0731388-A2 | An energy-sensitive resist material and a process for device fabrication using an energy-sensitive resist material | AT&T Corp. (US) | 1996-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | AKR1B1, ALDOA, AKR1C1 | CYP19A1 288/4885CA2 1742/4885CA1 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.